腎バイオマーカーの世界市場レポート 2025年

腎バイオマーカーの市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR8.5％で19億1,000万米ドルに成長します。予測期間の成長は、個別化医療と標的治療、日常臨床へのバイオマーカー検査の統合、アジアとラテンアメリカの新興市場、非侵襲的バイオマーカー検査法、ウェアラブルデバイスによる継続的モニタリングに起因しています。予測期間における主な動向には、包括的な疾患プロファイリングのためのマルチプレックスバイオマーカーパネル、バイオマーカー探索のためのAIと機械学習、バイオマーカーに基づくコンパニオン診断、在宅ヘルスケア環境におけるPOCバイオマーカー検査、早期発見と予防のためのバイオマーカーなどがあります。

老人および小児の腎臓患者の増加が、今後数年間の腎バイオマーカー市場の成長を牽引すると予想されます。老人性腎臓病患者とは、70歳以上の高齢者で慢性腎臓病（CKD）が進行した患者を指し、小児性腎臓病患者とは、小児期や若年成人期に腎臓障害と診断された患者を指します。腎バイオマーカーは、老年患者と小児患者の腎障害の重症度を評価するために不可欠です。例えば、2024年6月、政府機関であるオーストラリア保健福祉研究所は、慢性腎臓病（CKD）の死亡率が2021年に4.2％、2022年に6.2％上昇したと報告しました。このように、老人や小児の腎臓患者の増加が腎バイオマーカー市場の成長に寄与しています。

慢性腎臓病の罹患率の増加が、今後の腎バイオマーカー市場の成長を牽引すると予想されます。慢性腎臓病（CKD）とは、時間の経過とともに腎臓の機能が徐々に低下することを特徴とする疾患です。腎バイオマーカーは、CKDの進行の検出とモニタリングに不可欠であり、タイムリーな介入と個別化された治療戦略を可能にし、患者の予後改善につながります。例えば、2024年6月、政府機関であるオーストラリア保健福祉研究所は、CKD死亡率が2021年に4.2％、2022年に6.2％上昇したと報告しました。その結果、慢性腎臓病の有病率の増加が腎バイオマーカー市場の拡大に拍車をかけています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の腎バイオマーカーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の腎バイオマーカー市場：成長率分析
• 世界の腎バイオマーカー市場の実績：規模と成長, 2019-2024
• 世界の腎バイオマーカー市場の予測：規模と成長, 2024-2029, 2034F
• 世界の腎バイオマーカー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の腎バイオマーカー市場：バイオマーカーの種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 機能バイオマーカー
• アップレギュレーションタンパク質
• その他のバイオマーカーの種類
• 世界の腎バイオマーカー市場：診断技術別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 酵素免疫測定法
• 粒子増強比濁免疫測定法（PETIA）
• 比色分析
• 化学発光酵素免疫測定法（CLIA）
• 液体クロマトグラフィー質量分析法（LS-MS）
• 世界の腎バイオマーカー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 診断と病気の進行のモニタリング
• 研究在宅ケア
• 世界の腎バイオマーカー市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 診断検査室
• その他のエンドユーザー
• 世界の腎バイオマーカー市場：機能バイオマーカーのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クレアチニン
• 尿素
• シスタチンC
• 重炭酸塩
• 世界の腎バイオマーカー市場：アップレギュレーションタンパク質のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 好中球ゼラチナーゼ関連リポカリン（NGAL）
• 腎臓障害分子-1（KIM-1）
• インターロイキン-18（IL-18）
• 世界の腎バイオマーカー市場：その他のバイオマーカータイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 近位尿細管損傷バイオマーカー
• 急性腎障害バイオマーカー
• 慢性腎臓病バイオマーカー

第7章 地域別・国別分析

• 世界の腎バイオマーカー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の腎バイオマーカー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 腎バイオマーカー市場：競合情勢
• 腎バイオマーカー市場：企業プロファイル
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • BioPorto Diagnostics A/S Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • bioMerieux SA Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Randox Laboratories
• Siemens Healthineers
• Beckman Coulter Inc.
• Astute Medical Inc.
• Nexelis Company
• Sphingotec GmbH
• Bio-Rad Laboratories India Pvt. Ltd.
• Enzo Biochem Inc.
• PerkinElmer Inc.
• Novartis AG
• Alere Inc.
• AstraZeneca plc
• Bio-Techne Corp.
• DiaSorin S.p.A.
• EKF Diagnostics Holdings plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 腎バイオマーカー市場2029：新たな機会を提供する国
• 腎バイオマーカー市場2029：新たな機会を提供するセグメント
• 腎バイオマーカー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Renal biomarkers encompass proteins, lipids, genes, metabolites, proteomic patterns, or cells that are identified through urinalysis to assess the glomerular filtration rate of the kidney. A decrease in this rate is indicative of kidney damage, and renal biomarkers are instrumental in estimating the nature and severity of such injuries.

The main types of biomarkers in renal biomarker analysis include functional biomarkers, upregulated proteins, and other biomarker categories. Functional biomarkers are particularly significant as they allow the diagnosis of kidney injury in individuals with normal kidney function and in chronic kidney disease patients where the same injury would result in a substantial decrease in functional biomarkers like creatinine (Cr). Various diagnostic techniques, such as enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and liquid chromatography-mass spectrometry (LC-MS), are employed for renal biomarker analysis. These biomarkers find applications in diagnosis, disease progression monitoring, and research, and they are utilized by hospitals, diagnostic laboratories, and other end-users.

The renal biomarker market research report is one of a series of new reports from The Business Research Company that provides renal biomarker market statistics, including renal biomarker industry global market size, regional shares, competitors with a renal biomarker market share, detailed renal biomarker market segments, market trends and opportunities, and any further data you may need to thrive in the renal biomarker industry. This renal biomarker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The renal biomarkers market size has grown strongly in recent years. It will grow from $1.28 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increasing prevalence of kidney diseases, advances in medical diagnostics, aging population, growing awareness of early disease detection, adoption of point-of-care testing, rise in chronic diseases.

The renal biomarkers market size is expected to see strong growth in the next few years. It will grow to $1.91 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to personalized medicine and targetedTherapies, integration of biomarker testing into routine clinical practice, emerging markets in asia and latin america, non-invasive biomarker testing methods, continuous monitoring with wearable devices. Major trends in the forecast period include multiplex biomarker panels for comprehensive disease profiling, ai and machine learning for biomarker discovery, biomarker-based companion diagnostics, poc biomarker testing in home healthcare settings, biomarkers for early detection and prevention.

The increase in geriatric and pediatric renal patients is expected to drive the growth of the renal biomarkers market in the coming years. Geriatric renal patients refer to elderly individuals over the age of 70 with advanced chronic kidney disease (CKD), while pediatric renal patients are those diagnosed with renal disorders during childhood and young adulthood. Renal biomarkers are essential for assessing the severity of kidney injury in both geriatric and pediatric patients. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that chronic kidney disease (CKD) mortality rates rose by 4.2% in 2021 and 6.2% in 2022. Thus, the increasing number of geriatric and pediatric renal patients is contributing to the growth of the renal biomarkers market.

The increasing incidence of chronic kidney diseases is expected to drive the growth of the renal biomarkers market in the future. Chronic kidney disease (CKD) is a condition marked by the gradual decline in kidney function over time. Renal biomarkers are essential for detecting and monitoring the progression of CKD, enabling timely interventions and personalized treatment strategies, which lead to better patient outcomes. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that CKD mortality rates rose by 4.2% in 2021 and 6.2% in 2022. As a result, the growing prevalence of chronic kidney diseases is fueling the expansion of the renal biomarkers market.

Technological advancements have become a key trend gaining traction in the renal biomarkers market. Leading companies in the sector are focusing on developing innovative technologies to maintain their market position. For example, in March 2022, Nipro Medical Corporation, a US-based medical equipment manufacturer, introduced the SURDIAL DX. This advanced hemodialysis system incorporates cutting-edge technology to ensure optimal patient safety, comfort, and efficiency. It features modern design elements such as streamlined automated processes, ergonomic design, and a focus on improving the overall dialysis treatment experience.

Strategic collaborations and partnerships with start-ups and mid-sized companies are becoming increasingly prevalent in the renal biomarkers market. This approach allows major companies to expand their product and service offerings. In June 2022, Nordic Bioscience, a Denmark-based biomarker company, strengthened its collaboration with F. Hoffmann-La Roche Ltd., a multinational healthcare company. This collaboration involves the development of proprietary biomarkers related to tissue breakdown and build-up. Nordic Bioscience's ECM biomarkers are deemed essential for various chronic diseases, including kidney diseases. The partnership aims to improve clinical decisions in drug development and patient selection, ultimately enhancing patient outcomes.

In January 2024, Novartis AG, a Switzerland-based pharmaceutical company, acquired SanReno Therapeutics for an undisclosed amount. This rare acquisition of a Chinese biotech firm by a multinational company underscores China's potential in the global renal market and aligns with Novartis' commitment to innovative therapies for kidney diseases. SanReno Therapeutics is a China-based biopharmaceutical company that specializes in renal disease therapies.

Major companies operating in the renal biomarkers market include Abbott Laboratories, BioPorto Diagnostics A/S, Roche Holding AG, Thermo Fisher Scientific, bioMerieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter Inc., Astute Medical Inc., Nexelis Company, Sphingotec GmbH, Bio-Rad Laboratories India Pvt. Ltd., Enzo Biochem Inc., PerkinElmer Inc., Novartis AG, Alere Inc., AstraZeneca plc, Bio-Techne Corp., DiaSorin S.p.A., EKF Diagnostics Holdings plc, Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Merck KGaA, Myriad RBM Inc., Ortho Clinical Diagnostics Holdings plc, Quidel Corporation, R&D Systems Inc., Roche Diagnostics International Ltd., Sekisui Chemical Co. Ltd., Sysmex Corporation, Tosoh Bioscience Inc.

North America was the largest region in the renal biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the renal biomarkers market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the renal biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The renal biomarker market consists of revenues earned by entities by providing renal biomarker services such as integrated drug discovery, phenotypic assay, custom services, in vivo, biomarker identification, glomerular filtration diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal biomarker market also includes sales of point-of-care kit, antibody screening, cell-based diagnostic devices which are used in providing renal biomarker services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Renal Biomarkers Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on renal biomarkers market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for renal biomarkers ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The renal biomarkers market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Biomarker Type: Functional Biomarker; Up Regulated Protein; Other Biomarker Types
• 2) By Diagnostic Technique: Enzyme-Linked Immunosorbent Assay; Particle-Enhanced Turbidimetric Immunoassay (PETIA); Colorimetric Assay; Chemiluminescent Enzyme Immunoassay (CLIA); Liquid Chromatography Mass Spectrometry (LS-MS)
• 3) By Application: Diagnosis And Disease Progression Monitoring; Research Homecare
• 4) By End User: Hospitals; Diagnostic Laboratories; Other End Users
• Subsegments:
• 1) By Functional Biomarker: Creatinine; Urea; Cystatin C; Bicarbonate
• 2) By Up Regulated Protein: Neutrophil Gelatinase-Associated Lipocalin (NGAL); Kidney Injury Molecule-1 (KIM-1); Interleukin-18 (IL-18)
• 3) By Other Biomarker Types: Proximal Tubule Injury Biomarkers; Acute Kidney Injury Biomarkers; Chronic Kidney Disease Biomarkers
• Companies Mentioned: Abbott Laboratories; BioPorto Diagnostics A/S; Roche Holding AG; Thermo Fisher Scientific; bioMerieux SA
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Renal Biomarkers Market Characteristics

3. Renal Biomarkers Market Trends And Strategies

4. Renal Biomarkers Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Renal Biomarkers Growth Analysis And Strategic Analysis Framework

• 5.1. Global Renal Biomarkers PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Renal Biomarkers Market Growth Rate Analysis
• 5.4. Global Renal Biomarkers Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Renal Biomarkers Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Renal Biomarkers Total Addressable Market (TAM)

6. Renal Biomarkers Market Segmentation

• 6.1. Global Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Functional Biomarker
• Up Regulated Protein
• Other Biomarker Types
• 6.2. Global Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Enzyme-Linked Immunosorbent Assay
• Particle-Enhanced Turbidimetric Immunoassay (PETIA)
• Colorimetric Assay
• Chemiluminescent Enzyme Immunoassay (CLIA)
• Liquid Chromatography Mass Spectrometry (LS-MS)
• 6.3. Global Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Diagnosis And Disease Progression Monitoring
• Research Homecare
• 6.4. Global Renal Biomarkers Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Diagnostic Laboratories
• Other End Users
• 6.5. Global Renal Biomarkers Market, Sub-Segmentation Of Functional Biomarker, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Creatinine
• Urea
• Cystatin C
• Bicarbonate
• 6.6. Global Renal Biomarkers Market, Sub-Segmentation Of Up Regulated Protein, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Neutrophil Gelatinase-Associated Lipocalin (NGAL)
• Kidney Injury Molecule-1 (KIM-1)
• Interleukin-18 (IL-18)
• 6.7. Global Renal Biomarkers Market, Sub-Segmentation Of Other Biomarker Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Proximal Tubule Injury Biomarkers
• Acute Kidney Injury Biomarkers
• Chronic Kidney Disease Biomarkers

7. Renal Biomarkers Market Regional And Country Analysis

• 7.1. Global Renal Biomarkers Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Renal Biomarkers Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Renal Biomarkers Market

• 8.1. Asia-Pacific Renal Biomarkers Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Renal Biomarkers Market

• 9.1. China Renal Biomarkers Market Overview
• 9.2. China Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Renal Biomarkers Market

• 10.1. India Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Renal Biomarkers Market

• 11.1. Japan Renal Biomarkers Market Overview
• 11.2. Japan Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Renal Biomarkers Market

• 12.1. Australia Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Renal Biomarkers Market

• 13.1. Indonesia Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Renal Biomarkers Market

• 14.1. South Korea Renal Biomarkers Market Overview
• 14.2. South Korea Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Renal Biomarkers Market

• 15.1. Western Europe Renal Biomarkers Market Overview
• 15.2. Western Europe Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Renal Biomarkers Market

• 16.1. UK Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Renal Biomarkers Market

• 17.1. Germany Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Renal Biomarkers Market

• 18.1. France Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Renal Biomarkers Market

• 19.1. Italy Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Renal Biomarkers Market

• 20.1. Spain Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Renal Biomarkers Market

• 21.1. Eastern Europe Renal Biomarkers Market Overview
• 21.2. Eastern Europe Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Renal Biomarkers Market

• 22.1. Russia Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Renal Biomarkers Market

• 23.1. North America Renal Biomarkers Market Overview
• 23.2. North America Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Renal Biomarkers Market

• 24.1. USA Renal Biomarkers Market Overview
• 24.2. USA Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Renal Biomarkers Market

• 25.1. Canada Renal Biomarkers Market Overview
• 25.2. Canada Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Renal Biomarkers Market

• 26.1. South America Renal Biomarkers Market Overview
• 26.2. South America Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Renal Biomarkers Market

• 27.1. Brazil Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Renal Biomarkers Market

• 28.1. Middle East Renal Biomarkers Market Overview
• 28.2. Middle East Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Renal Biomarkers Market

• 29.1. Africa Renal Biomarkers Market Overview
• 29.2. Africa Renal Biomarkers Market, Segmentation By Biomarker Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Renal Biomarkers Market, Segmentation By Diagnostic Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Renal Biomarkers Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Renal Biomarkers Market Competitive Landscape And Company Profiles

• 30.1. Renal Biomarkers Market Competitive Landscape
• 30.2. Renal Biomarkers Market Company Profiles
  • 30.2.1. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. BioPorto Diagnostics A/S Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Thermo Fisher Scientific Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. bioMerieux SA Overview, Products and Services, Strategy and Financial Analysis

31. Renal Biomarkers Market Other Major And Innovative Companies

• 31.1. Randox Laboratories
• 31.2. Siemens Healthineers
• 31.3. Beckman Coulter Inc.
• 31.4. Astute Medical Inc.
• 31.5. Nexelis Company
• 31.6. Sphingotec GmbH
• 31.7. Bio-Rad Laboratories India Pvt. Ltd.
• 31.8. Enzo Biochem Inc.
• 31.9. PerkinElmer Inc.
• 31.10. Novartis AG
• 31.11. Alere Inc.
• 31.12. AstraZeneca plc
• 31.13. Bio-Techne Corp.
• 31.14. DiaSorin S.p.A.
• 31.15. EKF Diagnostics Holdings plc

32. Global Renal Biomarkers Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Renal Biomarkers Market

34. Recent Developments In The Renal Biomarkers Market

35. Renal Biomarkers Market High Potential Countries, Segments and Strategies

• 35.1 Renal Biomarkers Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Renal Biomarkers Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Renal Biomarkers Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer